Tumor Heterogeneity in Pancreatic Adenocarcinoma
Tumor Heterogeneity in Pancreatic Adenocarcinoma
复制标题
DOI：
10.1159/000477773
复制
发表时间：
2018-01-01
期刊：
影响因子：
5
通讯作者：
Pote, Nicolas
中科院分区：
文献类型：
--
作者：
Cros, Jerome;Raffenne, Jerome;Pote, Nicolas
胰腺癌是世界范围内最致命的恶性肿瘤之一，主要是由于其在晚期诊断频繁和其强烈的化疗耐药性。肿瘤异质性在组织学水平上是明显的，在肿瘤之间甚至在肿瘤内都是如此。最近的高通量分析已经证实，肿瘤间异质性大于肿瘤内异质性，这主要是由早期阶段的连续灾难性遗传事件和转移阶段的表观遗传修饰驱动的。虽然这种异质性可能会使寻找通用治疗方法变得复杂，但这些分析在基因组，转录组和代谢组学水平上区分了几种亚型，为一些人提供了新的治疗机会。(C)2017 S. Karger AG，巴塞尔。
Pancreatic adenocarcinoma is one of the deadliest malignancies worldwide, mainly due to frequent diagnosis at an advanced stage and its strong chemoresistance. Tumor heterogeneity is evident at the histological level, both between tumors and even within a tumor. Recent high-throughput analyses have confirmed that intertumor heterogeneity is greater than intratumor heterogeneity that is mostly driven by successive catastrophic genetic events in the early stage and by epigenetic modifications in the metastatic stage. While this heterogeneity may complicate the search for a universal cure, these analyses have distinguished several subtypes at the genomic, transcriptomic, and metabolomic levels that offer, for some, new therapeutic opportunities. (C) 2017 S. Karger AG, Basel.